Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Translational bottlenecks for biohybrid microrobots.

Science robotics·2026

Same author

Light-switchable swarming of biohybrid microrobots.

Science advances·2026

Same author

A STING-adjuvanted outer membrane vesicle nanoparticle vaccine vs. <i>Klebsiella pneumoniae</i> elicits broad capsule-type cross-protection.

PNAS nexus·2026

Same author

Integrating Experiments and Simulations to Uncover Size-Dependent Bioactivity in Cellular Nanodiscs.

Small (Weinheim an der Bergstrasse, Germany)·2026

Same author

Light-Triggered Accelerated Degradation of Surface-Bound Chemical Agents.

Journal of the American Chemical Society·2026

Same author

Cellular Nanoparticle-Probiotic Biohybrid for Multimodal Oral Therapy of Food Allergy.

ACS nano·2026

Same journal

Dual-Modal Phototherapeutic Nanoagents Eradicating Drug-Resistant Bacteria via Multi-Pathway of Membrane Disruption, Oxidative Damage, and Energy Metabolism Interference.

Advanced healthcare materials·2026

Same journal

Smartphone-Enabled Point-of-Care Biosensing Platform With Self-Calibration for Rapid Matrix-Resistant Detection of Multiple AMI Biomarkers in Whole Blood.

Advanced healthcare materials·2026

Same journal

Multimetal-Doped Nanoenzymes Reprogram Macrophages for Immunotherapy of Gouty Arthritis.

Advanced healthcare materials·2026

Same journal

Correction to "Fibrosis-on-Chip: A Guide to Recapitulate the Essential Features of Fibrotic Disease".

Advanced healthcare materials·2026

Same journal

A Collagen-based Scaffold Supports Tendon-to-bone Healing After Rotator Cuff Repair: An Integrated Translational Study.

Advanced healthcare materials·2026

Same journal

A Biomimetic Copper-Caffeic Acid Nanozyme Activates Cuproptosis and Pyroptosis by Mimicking the Neutrophil Enzymatic Cascade.

Advanced healthcare materials·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 16, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

Erythrocyte-inspired delivery systems.

Che-Ming J Hu¹, Ronnie H Fang, Liangfang Zhang

¹Department of NanoEngineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.

Advanced Healthcare Materials

|November 28, 2012

Summary

This summary is machine-generated.

Researchers are advancing red blood cell (RBC)-inspired delivery systems by mimicking natural RBC properties. These engineered systems, including carrier RBCs and membrane-camouflaged nanoparticles, promise next-generation nanomedicine.

More Related Videos

Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols

Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols

Published on: January 2, 2013

Related Experiment Videos

Last Updated: May 16, 2026

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Cell Squeezing as a Robust, Microfluidic Intracellular Delivery Platform

Published on: November 7, 2013

Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols

Antigens Protected Functional Red Blood Cells By The Membrane Grafting Of Compact Hyperbranched Polyglycerols

Published on: January 2, 2013

Area of Science:

Biomaterials Science
Nanotechnology
Drug Delivery

Background:

Natural red blood cells (RBCs) possess unique properties ideal for drug delivery.
Understanding RBC biology is crucial for designing effective artificial delivery systems.

Purpose of the Study:

To review recent advancements in RBC-inspired drug delivery systems.
To highlight strategies for engineering both natural and synthetic RBC-mimicking vehicles.
To discuss the potential of these systems in nanomedicine.

Main Methods:

Review of carrier RBCs engineered by loading natural RBCs with therapeutics.
Analysis of synthetic vehicles mimicking RBC mechanobiological and chemico-biological properties.
Discussion of RBC membrane-derived vesicles and RBC membrane-camouflaged nanoparticles.

Main Results:

Progress in developing carrier RBCs for direct therapeutic loading.
Engineering of synthetic systems that replicate RBC functions.
Successful synthesis and application of RBC membrane-derived vesicles and camouflaged nanoparticles.

Conclusions:

RBC-inspired delivery systems leverage natural RBC properties for enhanced therapeutic delivery.
These systems represent a significant step towards next-generation nanomedicine.
Extensive medical applications are anticipated for these innovative delivery platforms.